Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Thermo Fisher Scientific    TMO

THERMO FISHER SCIENTIFIC

(TMO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Thermo Fisher Scientific : to Buy Diagnostic Company for $10.1 Billion--Update

share with twitter share with LinkedIn share with facebook
share via e-mail
03/03/2020 | 07:14am EDT

By Carlo Martuscelli

Thermo Fisher Scientific Inc. agreed to pay about $10.1 billion for Qiagen NV, a molecular diagnostics company, bulking up in the field of infectious-disease testing.

Thermo Fisher, based in Waltham, Mass., and Qiagen, Venlo, the Netherlands, said in a joint release that a tie-up would expand the combined companies' specialty-diagnostics portfolio, improve their commercial and geographic reach and their life-sciences offerings.

Thermo Fisher provides analytical instruments and equipment for research, analysis and diagnostics for pharmaceutical companies and biotechnology laboratories. Last year, it generated $25.54 billion in revenue. Qiagen sales last year came in at $1.53 billion.

Qiagen, listed in Frankfurt, is a life sciences and molecular diagnostics supplier, active in infectious disease testing. It has been developing a test to detect the coronavirus, which is currently being evaluated at four Chinese hospitals. Interest by several suitors, however, precedes the recent spread of the disease. In December, before China disclosed the scale of the coronavirus outbreak there, Qiagen had said it was pursuing a go-it-alone strategy amid what it said were several expressions of interest.

The market for such suppliers is consolidating, and Thermo Fisher needs to bulk up, said Ulrich Huwald, an analyst at Warburg Research.

The deal values each Qiagen share at EUR39 ($43.30) in cash, representing a premium of around 23% to Monday's closing price. Including debt of $1.4 billion, the deal is worth $11.5 billion, Thermo Fisher said.

"This acquisition provides us with the opportunity to leverage our industry-leading capabilities and R&D expertise to accelerate innovation and address emerging health-care needs," Thermo Fisher Chairman, President and Chief Executive Marc N. Casper said.

The deal is expected to be completed in the first half of 2021, subject to regulatory approvals and other customary closing conditions, the company said.

 

Stocks mentioned in the article
ChangeLast1st jan.
QIAGEN N.V. 0.14% 42.99 Delayed Quote.27.19%
THERMO FISHER SCIENTIFIC 1.34% 340.26 Delayed Quote.4.74%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on THERMO FISHER SCIENTIFIC
05/22THERMO FISHER SCIENTIFIC INC. : Submission of Matters to a Vote of Security Hold..
AQ
05/21AVANTOR : Fitch Upgrades Avantor to 'BB-'; Outlook Stable
AQ
05/20THERMO FISHER SCIENTIFIC : Declares Quarterly Dividend
PR
05/19THERMO FISHER SCIENTIFIC : Publishes Offer Document for Voluntary Tender Offer f..
AQ
05/18GLOBAL MARKETS LIVE: Moderna soars on vaccine hopes, J.C. Penney files for Ch..
05/18THERMO FISHER SCIENTIFIC : OMass Announces Publication in Nature Methods
AQ
05/18THERMO FISHER SCIENTIFIC : 's Support of COVID-19 Response Continues to Expand w..
PR
05/18THERMO FISHER SCIENTIFIC : Publishes Offer Document for Voluntary Tender Offer f..
PR
05/15THERMO FISHER SCIENTIFIC : Helios 5 Laser PFIB Accelerates the Pace of Materials..
AQ
05/14THERMO FISHER SCIENTIFIC : Helios 5 Laser PFIB Accelerates the Pace of Materials..
PR
More news
Financials (USD)
Sales 2020 25 490 M
EBIT 2020 5 846 M
Net income 2020 3 487 M
Debt 2020 12 387 M
Yield 2020 0,25%
P/E ratio 2020 39,9x
P/E ratio 2021 32,0x
EV / Sales2020 5,76x
EV / Sales2021 5,31x
Capitalization 134 B
Chart THERMO FISHER SCIENTIFIC
Duration : Period :
Thermo Fisher Scientific Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends THERMO FISHER SCIENTIFIC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 19
Average target price 358,33 $
Last Close Price 340,26 $
Spread / Highest target 14,6%
Spread / Average Target 5,31%
Spread / Lowest Target -20,4%
EPS Revisions
Managers
NameTitle
Marc N. Casper Chairman, President & Chief Executive Officer
Mark P. Stevenson Chief Operating Officer & Executive Vice President
Stephen Williamson Chief Financial Officer & Senior Vice President
Ryan Snyder Chief Information Officer & Senior Vice President
Scott M. Sperling Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
THERMO FISHER SCIENTIFIC4.74%134 386
DANAHER CORPORATION3.11%111 893
INTUITIVE SURGICAL, INC.-4.80%65 632
ILLUMINA, INC.6.92%52 141
BOSTON SCIENTIFIC CORPORATION-20.59%51 167
SIEMENS HEALTHINEERS AG9.12%50 803